Background {#Sec1}
==========

Sepsis is characterized by a detrimental unbalanced host response to an infection, resulting in damage to tissues and dysfunction of organs \[[@CR1]\]. The outcome of sepsis is influenced by elements associated with the causative pathogen, the primary source of the infection and the host. With respect to the latter, genetic composition, age and comorbidities are considered to contribute \[[@CR1]\].

Diabetes mellitus is one of the most common comorbidities in patients with sepsis \[[@CR2]\]. Diabetes mellitus is associated with increased susceptibility to infection and sepsis \[[@CR3]\], likely due, at least in part, to compromised immune responses, such as adhesion, chemotaxis, phagocytosis and bacterial killing by immune cells \[[@CR3], [@CR4]\]. Diabetes mellitus can be accompanied by chronic organ dysfunction together with a state of low-grade chronic inflammation and activation of the vascular endothelium and the coagulation system \[[@CR4]--[@CR6]\], pathological alterations that in a more acute way also feature in patients with sepsis \[[@CR1]\]. Nonetheless, several studies have reported that diabetes does not change the mortality of sepsis \[[@CR7]--[@CR10]\]. Knowledge of the possible influence of diabetes mellitus on the host response to severe sepsis is limited. One investigation reported similar cytokine and procoagulant responses in critically ill patients with sepsis with and without pre-existing diabetes mellitus \[[@CR9]\], while another study reported elevated levels of endothelial cell activation markers in patients with diabetes mellitus and septic shock, relative to patients without diabetes mellitus \[[@CR11]\].

The primary objective of the present study was to provide more insight into the association between pre-existing diabetes mellitus and the host response to sepsis. To this end, we studied the host response in a large prospective cohort of well-documented critically ill patients with sepsis stratified according to the presence or absence of diabetes mellitus, using both a targeted approach (by measuring 15 plasma biomarkers reflective of pathways implicated in sepsis pathogenesis) and an unbiased approach (by analyzing the whole genome expression profiles in blood leukocytes). Additionally, considering that the common anti-diabetic drugs insulin \[[@CR12]--[@CR15]\] and metformin \[[@CR16]--[@CR18]\] can exert immune modulatory effects, the secondary objective of this study was to determine whether patients with diabetes mellitus treated with either of these medications presented with an altered host response to sepsis.

Methods {#Sec2}
=======

Study design, setting and patient identification {#Sec3}
------------------------------------------------

This study was conducted as part of the Molecular Diagnosis and Risk Stratification of Sepsis (MARS) project, a prospective observational study in the mixed intensive care units (ICUs) of two tertiary teaching hospitals (Academic Medical Center in Amsterdam and University Medical Center in Utrecht) (ClinicalTrials.gov identifier NCT01905033) \[[@CR19]--[@CR21]\]. Consecutive patients above 18 years of age admitted between January 2011 and July 2013 with an expected length of stay longer than 24 hours were included via an opt-out method approved by the medical ethical committees of the participating hospitals. All patient data were encrypted for privacy reasons and no separate ethical approval was required for sub-studies such as the one described here. Analyses were limited to the first 2.5 years of the MARS project, because host response measurements were restricted to this period for financial reasons. For every admitted patient the plausibility of an infection was assessed using a 4-point scale (ascending from none to possible, probable or definite) using the Center for Disease Control and Prevention and International Sepsis Forum consensus definitions, making use of all clinical, radiological and microbiological data, as previously described in detail \[[@CR19]\]. Sepsis was defined as the presence of infection diagnosed within 24 hours after ICU admission with a probable or definite likelihood, accompanied by at least one additional parameter as described in the 2001 International Sepsis Definitions Conference \[[@CR22]\]. Dedicated research physicians prospectively collected demographic data, details of comorbidities (including the Charlson comorbidity index \[[@CR23]\]), and daily clinical data and severity scores, including Acute Physiology and Chronic Health Evaluation (APACHE) IV \[[@CR24]\] and Sequential Organ Failure Assessment (SOFA) scores (the central nervous system was excluded) \[[@CR25]\].

Diabetes mellitus was defined as known history of type I or type II diabetes mellitus prior to ICU admission or by the use of oral anti-diabetic medication or insulin as chronic medication. The timing of the last dose of insulin or metformin prior to ICU admission was not registered; metformin was stopped after ICU admission. Cardiovascular insufficiency was defined as a medical history of congestive heart failure, chronic cardiovascular disease, peripheral vascular disease or cerebrovascular disease. Malignancy was defined by medical history of either non-metastatic solid tumor, metastatic malignancy or hematologic malignancy. Patients with a history of chronic renal insufficiency or with chronic intermittent hemodialysis or continuous ambulatory peritoneal dialysis were marked as renal insufficient \[[@CR21]\].

Specific organ failure was defined by a SOFA score ≥3, except for cardiovascular failure for which a score ≥1 was used (the central nervous system was excluded) \[[@CR26]\]. Shock was defined by the use of vasopressors (noradrenaline) for hypotension in a dose \>0.1 μg/kg/min during at least 50 % of the ICU day. Acute kidney injury and acute lung injury were defined using strict pre-set criteria \[[@CR27], [@CR28]\]. ICU-acquired complications were defined as events that started 2 days or more after ICU admission. The Municipal Personal Records Database was consulted to calculate survival after ICU admission. Patients readmitted to the same ICU or transferred from other ICUs were excluded, except when patients were referred to one of the study centers on the day of admission.

Plasma protein assays {#Sec4}
---------------------

Daily (on admission and at 6 a.m. thereafter) EDTA anti-coagulated leftover plasma harvested from blood obtained for regular patient care was stored within 4 hours after blood draw at -80 °C. Measurements were done in EDTA anti-coagulated plasma. Tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8, IL-1β, IL-10, IL-13, interferon-γ, soluble E-selectin, soluble intercellular adhesion molecule (ICAM)-1 and fractalkine were measured by FlexSet cytometric bead array (BD Biosciences, San Jose, CA, USA) using FACS Calibur (Becton Dickenson, Franklin Lakes, NJ, USA). Matrix metalloproteinase (MMP)-8, angiopoietin-1, angiopoietin-2, protein C, antithrombin (all R&D systems, Abingdon, UK) and D-dimer (Procartaplex, eBioscience, San Diego, CA, USA) were measured by Luminex multiplex assay using BioPlex 200 (BioRad, Hercules, CA, USA). C-reactive protein (CRP) was determined by immunoturbidimetric assay (Roche diagnostics), prothrombin time (PT) and activated partial thromboplastin time (aPTT) by using a photometric method with Dade Innovin Reagent or by Dade Actin FS Activated PTT Reagent, respectively (both Siemens Healthcare Diagnostics). Normal values were obtained in plasma from 27 age-matched and gender-matched healthy volunteers, included after providing written informed consent, with the exception of CRP, PT and aPTT (routine laboratory reference values).

Blood gene expression microarrays {#Sec5}
---------------------------------

Whole blood was collected in PAXgene™ tubes (Becton-Dickinson, Breda, the Netherlands) within 24 hours after ICU admission. Total RNA was isolated using the PAXgene blood mRNA kit (Qiagen, Venlo, the Netherlands) in combination with QIAcube automated system (Qiagen, Venlo, the Netherlands), according to the manufacturer's instructions. RNA (RNA integrity number \>6.0) was processed and hybridized to the Affymetrix Human Genome U219 96 array and scanned using the GeneTitan instrument at the Cologne Center for Genomics (CCG), Cologne, Germany, as described by the manufacturer (Affymetrix). Raw data scans (.CEL files) were read into the R language and environment for statistical computing (version 2.15.1; R Foundation for Statistical Computing, Vienna, Austria; [http://www.R-project.org/](http://www.r-project.org/)).

Pre-processing and quality control was performed using the Affy package version 1.36.1. Array data were background-corrected by Robust Multi-array Average, quantile-normalized and summarized by medianpolish using the expresso function (Affy package). The resultant 49,386 log-transformed probe intensities were filtered by means of a 0.5 variance cutoff using the genefilter method \[[@CR29]\] to recover 24,646 expressed probes in at least one sample. The occurrence of non-experimental chip effects was evaluated by means of the Surrogate Variable Analysis (R package version 3.4.0) and corrected by the empirical Bayes method ComBat \[[@CR30]\]. The non-normalized and normalized MARS gene expression data sets are available at the Gene Expression Omnibus public repository of the NCBI \[GEO:GSE65682\].

The 24,646 probes were assessed for differential abundance across healthy subject and patient samples by means of the limma method (version 3.14.4) \[[@CR31]\]. Supervised analysis (comparison between predefined groups) was performed by moderated *t* statistics. Throughout, significance was defined using the Benjamini-Hochberg (BH) multiple comparison adjusted probabilities, correcting for the 24,646 probes (false discovery rate \<5 %). Ingenuity Pathway Analysis (Ingenuity Systems IPA, [www.ingenuity.com](http://www.ingenuity.com)) was used to identify the associated canonical signaling pathways stratifying genes by over-expressed and under-expressed patterns. The Ingenuity gene knowledgebase was selected as reference and human species specified. All other parameters were left at default. The significance of association was assessed using Fisher's exact test.

Statistical analysis {#Sec6}
--------------------

All data distributions were tested for normality using the Shapiro-Wilk test and histogram plots. The Mann-Whitney *U* test or Kruskal-Wallis test was used to analyze continuous nonparametric data, presented as median and interquartile range (IQR, 25^th^ and 75^th^ percentiles). Continuous parametric data, presented as numbers (percentages) or as means ± standard deviation (SD), were analyzed using Student's *t* test or analysis of variance when appropriate. All categorical data were analyzed using the chi square test. As the biomarker data were not normally distributed, the Kruskal-Wallis test was used to analyze non-parametric data. A multivariable cox proportional hazard model was used to determine the association between diabetes mellitus and mortality. The covariables included in the model were BMI, patient age, gender, cardiovascular insufficiency, renal insufficiency and hypertension. A sensitivity analysis was conducted, correcting for the APACHE IV score.

All data were analyzed using R studio built under R version 3.0.2 (R Core Team 2013, Vienna, Austria) \[[@CR32]\]. The R package *survival* was used for the survival analysis. Multiple-comparison-adjusted (BH) *p* values \<0.05 were used to define the significance of plasma biomarkers.

Results {#Sec7}
=======

Patients, sepsis presentation and outcome {#Sec8}
-----------------------------------------

During the 2.5-year study period 1483 ICU admissions with sepsis were screened for eligibility; after exclusion of 250 patients (16.9 %) who were readmitted and 129 patients (8.7 %) who were transferred from other ICUs, 1104 patients remained for study inclusion, of whom 241 (21.8 %) had a medical history of diabetes mellitus. Patients with diabetes mellitus were older, had a higher BMI, a higher modified Charlson Comorbidity Index (calculated without the contribution of diabetes mellitus) and were admitted with more chronic comorbidities such as cardiovascular compromise, hypertension and renal insufficiency (Table [1](#Tab1){ref-type="table"}). Gender and race did not differ between groups. Insulin was noted as the medication for chronic disease in 54.8 % of patients with diabetes mellitus, and metformin was used in 47.3 % of the patients with diabetes mellitus.Table 1Baseline characteristics, clinical course and outcome of critically ill patients with sepsis with or without diabetes mellitusDiabetes mellitusNo diabetes mellitus*P* valuePatients, *n* (%)241 (21.8 %)863 (78.2 %)Demographic dataAge, mean (SD), years66.0 (11.6)59.8 (15.2)\<0.0001Gender male, *n* (%)144 (59.8 %)527 (61.1 %)0.77Body mass index mean (SD)28.9 (7.7)25.2 (5.4)\<0.0001Race, white, *n* (%)202 (83.8 %)771 (89.3 %)0.10Medical admission, *n* (%)188 (78.0 %)630 (73.0 %)0.13Chronic comorbidity, *n* (%) Cardiovascular compromise103 (42.7 %)160 (18.5 %)\<0.0001 Chronic obstructive pulmonary disease37 (15.4 %)124 (14.4 %)0.74 Hypertension129 (53.5 %)211 (24.4 %)\<0.001 Malignancy61 (25.3 %)215 (24.9 %)0.94 Renal insufficiency57 (23.7 %)104 (12.1 %)\<0.001 Modified Charlson Comorbidity Index^a^, median (IQR)5 (3--6)4 (2­--5)\<0.0001Diabetic medication, *n* (%) Insulin133 (55.2 %) Metformin114 (47.3 %)- Glimepiride22 (9.1 %)- Glibenclamide1 (0.4 %)- Gliclazide5 (2.1 %)- Tolbutamide24 (10.0 %)-Severity of disease on ICU admission APACHE IV Score, median (IQR)82 (66--104)79 (52--101)0.03 APACHE APS, median (IQR)67 (52--87)67 (50--85)0.44 SOFA score, median (IQR)7 (5--9)7 (5--9)0.55 Mechanical ventilation, *n* (%)155 (64.3 %)601 (69.6 %)0.12 Organ failure, *n* (%)202 (83.8 %)721 (83.5 %)0.48 Shock, *n* (%)78 (32.4 %)295 (34.2 %)0.65 Acute kidney injury, *n* (%)96 (39.8 %)308 (35.7 %)0.26 Acute lung injury, *n* (%)61 (25.3 %)219 (25.4 %)\>0.99 Acute myocardial infarction, *n* (%)7 (2.9 %)17 (2.0 %)0.45Laboratory measurements first 24 hours after ICU admission (peak values), median (IQR) Glucose (mmol/L)12.9 (10.5--16.2)9.5 (7.9--11.5)\<0.0001 Lactate (mmol/mL)3.1 (1.8--4.8)2.5 (1.6--4.9)0.14 Creatinin (μmol/L135 (89--197)109 (71--181)\<0.0001Source of infection, *n* (%) Pulmonary103 (42.7 %)430 (49.8 %)0.07 Abdominal53 (22.0 %)188 (21.8 %)\>0.99 Urosepsis42 (17.4 %)85 (9.8 %)0.002 Cardiovascular infection29 (12.0 %)124 (14.4 %)0.41 Skin14 (5.8 %)36 (4.2 %)0.32Causative pathogens^b^, *n* (%) Gram-negative bacteria141 (58.5 %)444 (51.4 %)0.06 Gram-positive bacteria102 (42.3 %)386 (44.7 %)0.55 Fungi/yeasts26 (10.8 %)80 (9.3 %)0.56 Virus11 (4.6 %)46 (5.3 %)0.76 Other17 (7.1 %)54 (6.3 %)0.78 Unknown31 (12.9 %)134 (15.6 %)0.36Outcome ICU length of stay (days), median (IQR)4 (2--9)4 (2--10)0.56 Hospital length of stay (days), median (IQR)21 (10--40)23 (11--47)0.08 Complications, *n* (%)  None199 (82.6 %)702 (81.3 %)0.70  Acute kidney injury25 (10.4 %)69 (8.0 %)0.30  Acute lung injury10 (4.1 %)41 (4.8 %)0.74  ICU-acquired weakness13 (5.4 %)60 (7.0 %)0.46  Acute myocardial infarction2 (0.8 %)8 (0.9 %)\>0.99  ICU-acquired infection22 (9.1 %)88 (10.2 %)0.63Mortality, *n* (%) ICU47 (19.5 %)180 (20.9 %)0.65 Hospital78 (32.4 %)270 (31.3 %)0.83 Day 3072 (29.9 %)233 (27.0 %)0.44 Day 6090 (37.3 %)275 (31.9 %)0.15 Day 9095 (39.4 %)308 (35.7 %)0.32^a^Modified Charlson Index was calculated without the contribution of diabetes mellitus. ^b^Percentages of causative pathogens were calculated using the total number of infections as denominator. As multiple pathogens could be assigned as causative, percentages \>100 % may occur. *APACHE* Acute Physiology and Chronic Health Evaluation, *APS* Acute Physiology Score, *ICU* intensive care unit, *IQR* interquartile range

Disease severity on ICU admission was comparable in patients with and without known diabetes mellitus. Although the APACHE IV score was higher in diabetes mellitus patients, the difference compared to patients without diabetes mellitus was driven by differences in age and comorbidities, as the Acute Physiology Score (APS) was comparable between groups. Patients with known diabetes mellitus were more often admitted with urosepsis (17.4 % versus 9.8 % in patients without diabetes mellitus, *p* = 0.002); other sources of infection were not different between groups. Causative pathogens were comparable in patients with and without diabetes mellitus, although there was a trend towards more gram-negative infections in patients with history of diabetes mellitus (Table [1](#Tab1){ref-type="table"}).

Patients with and without diabetes mellitus did not differ in ICU or hospital length of stay, or development of ICU-acquired complications (Table [1](#Tab1){ref-type="table"}). In addition, mortality did not differ between groups during the period up to 90 days after ICU admission (Table [1](#Tab1){ref-type="table"}). Diabetes mellitus was also not associated with increased risk of mortality at 90 days after correction for baseline differences in BMI, age, gender, cardiovascular insufficiency, renal insufficiency and hypertension (hazard ratio (HR) 0.90, 95 % CI 0.69, 1.15), nor did they differ when corrected for APACHE IV score (HR 1.02, 95 % CI 0.81, 1.29).

Plasma biomarkers reflective of host response pathways implicated in sepsis pathogenesis {#Sec9}
----------------------------------------------------------------------------------------

Relative to healthy controls, patients with sepsis had increased acute phase protein response (elevated plasma CRP concentrations), profound activation of the cytokine network (elevated plasma levels of IL-6, IL-8 and IL-10), the vascular endothelium (elevated plasma concentrations of soluble E-selectin, soluble ICAM-1, fractalkine and angiopoietin-2, and reduced levels of angiopoietin-1) and the coagulation system (elevated D-dimer levels, prolonged PT and aPTT, and reduced levels of the anticoagulant proteins protein C and antithrombin), both on ICU admission (Fig. [1](#Fig1){ref-type="fig"}) and on days 2 and 4 (Additional file [1](#MOESM1){ref-type="media"}: Table S1). Systemic inflammation was further demonstrated by elevated levels of MMP-8. None of these responses differed between patients with and without diabetes mellitus. The plasma concentrations of TNF-α, interferon-γ, IL-1β and IL-13 were undetectable or very low in the vast majority of patients and were not different between groups (data not shown).Fig. 1Plasma biomarkers reflective of host response pathways implicated in sepsis pathogenesis on ICU admission in sepsis patients with and without diabetes mellitus. *Boxes* show median and lower and upper quartiles (*solid horizontal lines*) with their respective 1.5 IQR (*whiskers*) (as specified by Tukey). *Dotted lines* indicate median values obtained in 27 healthy age-matched subjects. *CRP* C-reactive protein, *IL* interleukin, *ICAM* intercellular adhesion molecule, *MMP* matrix metalloproteinase, *PT* prothrombin time, *APT* activated partial thromboplastin time

Blood leukocyte transcriptome analysis {#Sec10}
--------------------------------------

Using an unbiased approach, we compared the blood leukocyte transcriptome of patients with diabetes mellitus (*n* = 108) and those without diabetes mellitus (*n* = 382). This analysis comprised the subgroup of patients enrolled during the first 1.5 years of this study (Additional file [2](#MOESM2){ref-type="media"}: Table S2). Demographic differences and differences in comorbidities between patients with and without diabetes mellitus were similar to those found in the complete cohort. Likewise, disease severity at presentation and outcomes did not differ between patients with and without diabetes mellitus. At first, the genome-wide blood gene expression profiles of these sepsis patients were compared to 42 healthy controls. Patients both with and without diabetes mellitus had strong transcriptional alterations (Fig. [2a](#Fig2){ref-type="fig"}), and 74 % of the expressed gene content was significantly altered in both sepsis groups, with no differences between patients with sepsis with and without diabetes mellitus (Fig. [2b](#Fig2){ref-type="fig"}). Biological pathway analysis revealed commonly over-expressed genes associated with typical pro-inflammatory, anti-inflammatory, Toll-like receptor and metabolic signaling pathways (Fig. [2c](#Fig2){ref-type="fig"}). Common under-expressed genes were associated with a variety of T cell signaling pathways and translation (EIF2) and metabolic (mTOR) signaling pathways (Fig. [2c](#Fig2){ref-type="fig"}).Fig. 2Blood transcriptional profiling of patients with sepsis with and without diabetes mellitus (*DM*). **a** Volcano plot representation of differentially expressed genes of whole-blood leukocytes in sepsis patients discordant for diabetes mellitus, each compared to healthy controls. *Red dots* denote over-expressed genes and *blue dots* denote under-expressed genes. **b** Spearman correlation analysis of the transcriptional alterations in patients with sepsis with or without diabetes mellitus revealed almost perfect correlation. *rho* Spearman's correlation coefficient, fold change (*FC*). **c** Ingenuity pathway analysis of commonly over-expressed (*red bars*) and under-expressed (*turquoise bars*) genes. --log10 (Benjamini-Hochberg (*BH*)) *p* value negative log~10~-transformed corrected for multiple comparisons

Association with insulin and metformin treatment {#Sec11}
------------------------------------------------

To obtain insight into a possible effect of chronic insulin treatment on the host response to sepsis in patients with diabetes mellitus, we first determined differences in the presentation and outcome of patients with diabetes mellitus who were on insulin therapy prior to ICU admission and those who were not (Table [2](#Tab2){ref-type="table"}). Relative to patients with diabetes mellitus who were not on chronic insulin therapy, patients treated with insulin were younger, less frequently male and had less cardiovascular insufficiency, less malignancy, and more renal insufficiency. Among the patients treated with insulin, 36.1 % also received oral anti-diabetic medication.Table 2Baseline characteristics, clinical course and outcome of patients with diabetes mellitus and sepsis, who were stratified according insulin or metformin use prior to ICU admissionDiabetes mellitus treated with insulinDiabetes mellitus not treated with insulin*P* valueDiabetes mellitus treated with metforminDiabetes mellitus not treated with metformin*P* valuePatients, *n* (%)133 (55.2 %)108 (44.8 %)114 (47.3 %)127 (52.7 %)Demographic dataAge mean (SD), years64.3 (12.5)68.1 (10.0)\<0.0167.0 (10.4)65.1 (12.6)0.19Gender male, *n* (%)71 (53.4 %)73 (67.6 %)0.0478 (68.4 %)66 (52.0 %)0.01Body mass index mean (SD)28.9 (8.5)28.9 (6.7)0.9829.0 (7.7)28.8 (7.9)0.86Race, white, *n* (%)115 (86.5 %)87 (80.6 %)0.4597 (85.1 %)105 (82.7 %)0.66Medical admission, *n* (%)104 (78.2 %)84 (77.8 %)\>0.9992 (80.7 %)96 (75.6 %)0.37Chronic comorbidity, *n* (%) Cardiovascular compromise49 (36.8 %)54 (50.0 %)0.0548 (42.1 %)55 (43.3 %)0.89 COPD22 (16.5 %)15 (13.9 %)0.5916 (14.0 %)21 (16.5 %)0.59 Hypertension66 (49.6 %)63 (58.3 %)0.2065 (57.0 %)64 (50.4 %)0.34 Malignancy25 (18.8 %)36 (33.3 %)0.0232 (28.1 %)29 (22.8 %)0.38 Renal insufficiency41 (30.8 %)16 (14.8 %)\<0.0110 (8.8 %)47 (37.0 %)\<0.001 Modified Charlson Comorbidity Index^a^4 (3--6)5 (4--6)0.015 (3--6)5 (3--6)0.85Diabetic medication, *n* (%) Insulin132 (100.0 %)-44 (38.6 %)88 (69.3 %)\<0.001 Metformin44 (33.1 %)70 (64.8 %)\<0.001114 (100.0 %)- Glimepiride5 (3.8 %)17 (15.7 %)\<0.0118 (15.8 %)4 (3.1 %)\<0.001 Glibenclamide-1 (0.9 %)0.471 (0.9 %)- Gliclazide2 (1.5 %)3 (2.8 %)0.662 (1.8 %)3 (2.4 %)\>0.99 Tolbutamide3 (2.3 %)21 (19.4 %)\<0.0018 (7.0 %)16 (12.6 %)0,18 Any oral anti-diabetic medication48 (36.1 %)89 (82.4 %)\<0.001114 (100.0 %)23 (18.1 %)\<0.0001Severity of disease on ICU admission APACHE IV score, median (IQR)82 (67--106)83 (65--103)0.9783 (64--106)82 (68--104)0.62 APACHE APS, median (IQR)68 (52--87)65 (51--85)0.5466 (50--90)68 (54--86)0.56 SOFA score, median (IQR)7 (6--9)7 (5--9)0.587 (5--8)8 (6--10)0.05 Mechanical ventilation, *n* (%)79 (59.4 %)76 (70.4 %)0.0770 (61.4 %)85 (66.9 %)0.41 Organ failure, *n* (%)115 (86.5 %)87 (80.6 %)0.5694 (82.5 %)108 (85.0 %)0.77 Shock, *n* (%)46 (34.6 %)32 (29.6 %)0.5028 (24.6 %)50 (39.4 %)0.02 Acute kidney injury, *n* (%)56 (42.1 %)40 (37.0 %)0.4350 (43.9 %)46 (36.2 %)0.22 Acute lung injury, *n* (%)31 (23.3 %)30 (27.8 %)0.4630 (26.3 %)31 (24.4 %)0.79 Acute myocardial infarction, *n* (%)4 (3.0 %)3 (2.8 %)\>0.995 (4.4 %)2 (1.6 %)0.25Laboratory measurements first 24 hours after ICU admission (peak values), median (IQR) Glucose (mmol/L)12.8 (10.8--16.6)12.9 (10.0--15.5)0.1712.5 (10.3--15.5)13.3 (10.6--16.7)0.43 Lactate (mmol/mL)3.2 (2-4.9)2.9 (1.6--4.5)0.352.7 (1.6--4.5)3.3 (2--5.1)0.22 Creatinin (μmol/L)146 (89--228)123 (92--173)0.08124 (87--170)151 (95--255)0.01Outcome Length of ICU stay (days), median (IQR)4 (2-9)4 (2-9)\>.995 (2-10)4 (2-9)0.65 Hospital length of stay (days), median (IQR)21 (11--44)21 (9--38)0.5522 (11--44)20 (10--40)0.44 Complications, *n* (%)  None108 (81.2 %)91 (84.3 %)0.6096 (84.2 %)103 (81.1 %)0.62  Acute kidney injury13 (9.8 %)12 (11.1 %)0.8211 (9.6 %)14 (11.0 %)0.84  Acute lung injury7 (5.3 %)3 (2.8 %)0.354 (3.5 %)6 (4.7 %)0.76  ICU-acquired weakness6 (4.5 %)7 (6.5 %)0.566 (5.3 %)7 (5.5 %)\>0.99  Acute myocardial infarction1 (0.8 %)1 (0.9 %)\>0.992 (1.8 %)-0.22  ICU-acquired infection16 (12.0 %)6 (5.6 %)0.138 (7.0 %)14 (11.0 %)0.39Mortality, *n* (%) ICU23 (17.3 %)24 (22.2 %)0.4218 (15.8 %)29 (22.8 %)0.20 Hospital43 (32.3 %)35 (32.4 %)\>0.9932 (28.1 %)46 (36.2 %)0.22 Day 3041 (30.8 %)31 (28.7 %)0.7731 (27.2 %)41 (32.3 %)0.47 Day 6050 (37.6 %)40 (37.0 %)\>0.9938 (33.3 %)52 (40.9 %)0.25 Day 9051 (38.3 %)44 (40.7 %)0.7941 (36.0 %)54 (42.5 %)0.30^a^Modified Charlson Index was calculated without the contribution of diabetes mellitus. *APACHE* Acute Physiology and Chronic Health Evaluation, *APS* Acute Physiology Score, *COPD* chronic obstructive pulmonary disease, *ICU* intensive care unit

The course and mortality of sepsis was similar in patients with diabetes mellitus who were and were not on chronic insulin therapy (Table [2](#Tab2){ref-type="table"}). Chronic insulin treatment did not influence the mortality risk at 90 days when corrected for baseline differences in age, gender, malignancy and renal insufficiency (HR 1.10, 95 % CI 0.72, 1.69) nor when corrected for the APACHE IV score (HR 0.87, 95 % CI 0.58, 1.30). Plasma biomarker levels suggestive of systemic inflammation, activation of the coagulation system and the vascular endothelium did not differ between patients on chronic insulin therapy and those who were not (Fig. [3](#Fig3){ref-type="fig"}). Similarly, the blood leukocyte genomic response did not differ between these two groups (Additional file [3](#MOESM3){ref-type="media"}: Figure S1A).Fig. 3Host response on ICU admission in patients admitted with insulin-treated versus non-insulin-treated diabetes mellitus. *Boxes* show the median, lower quartile and upper quartiles (*solid horizontal lines*) and their respective 1.5 IQR (*whiskers*) (as specified by Tukey). *Dotted lines* indicate median values obtained in 27 healthy age matched subjects. *CRP* C-reactive protein, *IL* interleukin, *ICAM* intercellular adhesion molecule, *MMP* matrix metalloproteinase, *PT* prothrombin time, *APT* activated partial thromboplastin time

To obtain insight into a possible influence of prior metformin treatment on the host response to sepsis in patients with diabetes mellitus, we first assessed variance in the presentation and outcome of patients with diabetes mellitus who had received metformin prior to ICU admission and those who had not (Table [2](#Tab2){ref-type="table"}). Relative to diabetes mellitus patients who were not on chronic metformin treatment, patients treated with metformin were more frequently male and had less renal insufficiency. Metformin treatment was not associated with an altered course of disease or the case fatality rate of sepsis (Table [2](#Tab2){ref-type="table"}). Chronic metformin treatment did not influence the mortality risk at 90 days when corrected for baseline differences in age, gender and renal insufficiency (HR 0.75, 95 % CI 0.48, 1.15) nor when corrected for the APACHE IV score (HR 0.81, 95 % CI 0.54, 1.21). The host response to sepsis, as measured by plasma protein markers (Fig. [4](#Fig4){ref-type="fig"}) and the whole genome transcriptome in blood leukocytes (Additional file [3](#MOESM3){ref-type="media"}: Figure S1B) did not differ between patients with diabetes mellitus who had and had not received prior metformin therapy.Fig. 4Host response on ICU admission in patients admitted with metformin-treated versus non-metformin-treated diabetes mellitus. Shown are the median, lower and upper quartile (*solid horizonal lines*) and their respective 1.5 IQR (*whiskers*) (as specified by Tukey). *Dotted lines* indicate median values obtained in 27 healthy age matched subjects. *CRP* C-reactive protein, *IL* interleukin, *ICAM* intercellular adhesion molecule, *MMP* matrix metalloproteinase, *PT* prothrombin time, *APT* activated partial thromboplastin time

Discussion {#Sec12}
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The main finding of this investigation is that sepsis patients with a medical history of diabetes mellitus have a similar host response upon ICU admission when compared with sepsis patients without known diabetes mellitus. In addition, pre-existing diabetes mellitus did not alter sepsis-associated mortality up to 90 days after ICU admission. We also demonstrated that amongst patients with diabetes mellitus two common diabetes mellitus therapies, insulin and metformin, are not associated with a modified host response or sepsis outcome.

Our data on similar case fatality rates of sepsis in critically ill patients with or without a known history of diabetes mellitus are in accordance with previous studies \[[@CR7], [@CR9], [@CR10]\]. Notably, however, other investigations have reported increased \[[@CR33], [@CR34]\] or decreased \[[@CR35]\] sepsis mortality in patients with diabetes mellitus. These latter studies differ from ours in that they did not merely include patients with sepsis in need of intensive care, and as a consequence thereof reported much lower mortality rates than observed in our sepsis ICU population. Together these data suggest that the association between diabetes mellitus and sepsis outcome depends, at least in part, on the (sub)acute severity of disease.

Diabetes mellitus was not associated with altered host responses during sepsis, suggesting that diabetes-mellitus-related low-grade chronic inflammation, activation of the vascular endothelium and the coagulation system \[[@CR4]--[@CR6]\], does not influence acute infection-induced alterations in these pathways. In accordance, a previous study likewise reported comparable markers of coagulation and inflammation in patients with diabetes mellitus and sepsis \[[@CR9]\]. Similarly, diabetes mellitus was not associated with altered cytokine or procoagulant responses in patients presenting at the emergency room with community-acquired pneumonia \[[@CR36]\].

We measured several plasma biomarkers of endothelial cell activation (soluble E-selectin, soluble ICAM-1 and fractalkine) \[[@CR37]\] and barrier function (angiopoietin-1 and angiopoietin-2) \[[@CR37]\], neither of which was modified in patients with diabetes mellitus. The vascular endothelium is of great interest in the context of diabetes mellitus and sepsis, because chronic diabetes mellitus can cause a dysfunctional endothelium leading to diabetes-mellitus-related atherosclerosis \[[@CR38]\], and upregulation of ICAM-1, vascular cell adhesion molecule-1 (VCAM-1) and E-selectin, resulting in increased adherence of neutrophils \[[@CR39]\]. An earlier investigation reported endothelial cell activation plasma markers in patients presented to the emergency department with clinically suspected infection \[[@CR11]\]. In this cohort soluble ICAM-1 and VCAM-1 did not differ between patients with and without diabetes mellitus; however, plasma-soluble E-selectin and soluble fms-like tyrosine kinase-1 were higher in patients with diabetes mellitus; notably, unlike our investigation, diabetes mellitus patients presented with more severe disease when compared with patients who did not have diabetes mellitus, possibly confounding the interpretation of plasma biomarker measurements \[[@CR11]\].

Similarities in patients with sepsis who did and did not have diabetes mellitus were not exclusive to plasma biomarkers, as we also observed no differences in their blood leukocyte transcriptomes. Almost identical alterations were evident in both groups of patients as compared to healthy controls; alterations that were strongly attuned to a "common host/sickness response" \[[@CR20]\]. Over-expression of typical pro-inflammatory, anti-inflammatory and metabolic pathways in parallel with under-expression of a plethora of T cell related pathways were overarching features of the common response. Notably, key cellular metabolic pathways (mitochondrial dysfunction, EIF2 and MTOR signaling) were also similarly altered in patients with and without diabetes mellitus.

Our study is the first to analyze sepsis patients with insulin-treated compared to patients with non-insulin-treated diabetes mellitus, revealing no differences between groups in the presentation or outcome of sepsis, or the host responses. An earlier investigation reported increased disease severity in critically ill patients with insulin-treated diabetes mellitus relative to all other patients on ICU admission \[[@CR10]\]. However, this study is difficult to compare with ours, because it was not restricted to patients with sepsis and the comparator group consisted of both patients with diabetes mellitus not treated with insulin and patients without diabetes mellitus \[[@CR10]\]. As insulin can modify inflammatory and procoagulant responses independently of glucose levels \[[@CR12]--[@CR15]\] we sought to compare the host response in insulin-treated versus non-insulin-treated patients with diabetes mellitus. Pre-existing insulin treatment did not affect any of the plasma host response biomarkers or the blood genomic response in our cohort, possibly due to the more profound alterations caused by the sepsis response in both groups.

Considering the established anti-inflammatory effects of metformin \[[@CR16], [@CR17]\], we compared the presentation and outcome of sepsis and the host responses in metformin-treated and non-metformin-treated patients with diabetes mellitus. Metformin had no effect on the outcome or host response, despite the fact that patients with non-metformin-treated diabetes mellitus were admitted with significantly higher rates of shock. Metformin may decrease mortality in other patient populations. In patients with diabetes mellitus who underwent cardiac surgery, preadmission metformin use was associated with a decreased postoperative morbidity rate, including from infections, and with a substantial decrease in inpatient mortality \[[@CR40]\]. In a general population of medical and surgical ICU patients with type II diabetes mellitus, preadmission metformin use was associated with reduced 30-day mortality; however, this was not statistically significant in the subgroup of patients with sepsis \[[@CR41]\]. Blood transcriptome data obtained from patients with diabetes mellitus and sepsis, who were or were not treated with metformin suggests no influence of gluconeogenesis antagonism on systemic genomic responses.

Our study has strengths and limitations. It is the first to report on the potential influence of diabetes mellitus on the blood genomic response to sepsis and the first of its size to extensively study the association between treatments for diabetes mellitus and the host response to sepsis. Due to our prospective data collection we present a well-defined sepsis population with detailed clinical and laboratory information. As diabetes mellitus was registered based on medical history or the use of anti-diabetic medication, the possibility of previously unrecognized or new-onset diabetes mellitus cannot be excluded and could lead to misclassification of diabetic status. The type of diabetes mellitus was not registered and we cannot provide information on diabetes mellitus control prior to ICU admission, because HbA1c was not routinely measured and diabetes mellitus care is usually provided by general practitioners. In addition, as plasma protein biomarkers were measured at intervals, relative rapid changes in biomarker distribution could not be analyzed.

Conclusion {#Sec13}
==========

Neither diabetes mellitus nor preadmission insulin or metformin use are associated with altered disease severity, outcome or host response in patients with sepsis requiring intensive care.
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